Caribou Biosciences, Inc.

Investigation Alert Caribou Biosciences: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm Regarding Investigation

Caribou Biosciences, Inc. (NASDAQ: CRBU)

Johnson Fistel, LLP is investigating potential claims on behalf of Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU) against certain of its officers and directors.

If you are a current, long-term shareholder of Caribou Biosciences, Inc. you may have standing to hold Caribou Biosciences, Inc. harmless from the alleged harm caused by the Company’s officers and directors by making them personally responsible. You may also be able to assist in reforming the Company’s corporate governance to prevent future wrongdoing.

Recently a class action lawsuit was filed against the company. The complaint alleges that defendants made false statements and/or concealed that: (i) the treatment effect of the Company’s product candidate, CB-010, was not as durable as defendants had led investors to believe; (ii) accordingly, CB-010’s clinical and commercial prospects were overstated; and (iii) as a result, documents issued in connection with Caribou’s initial public offer and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.

Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Telephone: (619) 814-4471